Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.48 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL569579 | 0.88 | HSD17B10 (0.54) | L3MBTL1KDM4EALDH1A1HPGDNCEH1 | |
| SCHEMBL13302182 | 0.81 | CYP11B1 (0.50) | KDM4EALDH1A1HPGDNPSR1NR4A2 | |
| SCHEMBL3332506 | 0.80 | ABL1 (0.47) | L3MBTL1KDM4EALDH1A1HPGDNPSR1 | |
| SCHEMBL3334695 | 0.76 | KDM4E (0.44) | L3MBTL1KDM4EALDH1A1HPGDNPSR1 | |
| SCHEMBL819329 | 0.75 | L3MBTL1 (0.50) | L3MBTL1KDM4EALDH1A1HPGDNPSR1 | |
| SCHEMBL13302179 | 0.74 | ALDH1A1 (0.48) | KDM4EALDH1A1HPGDNPSR1SMN1; SMN2 | |
| SCHEMBL3397273 | 0.74 | KDM4E (0.51) | L3MBTL1KDM4EALDH1A1HPGDNPSR1 | |
| SCHEMBL31187398 | 0.74 | MEN1 (0.54) | L3MBTL1KDM4EALDH1A1HPGDNPSR1 | |
| SCHEMBL358977 | 0.74 | MEN1 (0.54) | L3MBTL1KDM4EALDH1A1HPGDNPSR1 | |
| SCHEMBL25599320 | 0.72 | KDM4E (0.44) | L3MBTL1KDM4EALDH1A1HPGDNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12576055-B2 | Disease detection and treatment based on trimethyl-lysine levels | THE CLEVELAND CLINIC FOUNDATION (US) | 2026-03-17 | — | — | US | disclosed |
| WO-2024243289-A2 | GUT MICROBE DERIVED AROMATIC AMINO ACID METABOLITES FOR DETECTION AND TREATMENT OF DISEASE | THE CLEVELAND CLINIC FOUNDATION (US) | 2024-11-28 | — | — | WO | disclosed |
| US-20240165131-A1 | TREATING AND PREVENTING DISEASE WITH TMA AND TMAO LOWERING AGENTS | THE CLEVELAND CLINIC FOUNDATION | 2024-05-23 | — | — | US | disclosed |
| US-20240139120-A1 | TREATING DISEASE AND PROMOTING WEIGHT LOSS BY INHIBITING THE TMA/FMO3/TMAO PATHWAY | THE CLEVELAND CLINIC FOUNDATION | 2024-05-02 | — | — | US | disclosed |
| US-11911399-B2 | Treating and preventing disease with TMA and TMAO lowering agents | THE CLEVELAND CLINIC FOUNDATION (US) | 2024-02-27 | — | — | US | disclosed |
| EP-4299064-A2 | TREATING DISEASE AND PROMOTING WEIGHT LOSS BY INHIBITING THE TMA/FMO3/TMAO PATHWAY | THE CLEVELAND CLINIC FOUNDATION (US) | 2024-01-03 | — | — | EP | disclosed |
| EP-3641748-B1 | TREATING DISEASE AND PROMOTING WEIGHT LOSS BY INHIBITING THE TMA/FMO3/TMAO PATHWAY | CLEVELAND CLINIC FOUND (US) | 2023-11-29 | — | — | EP | disclosed |
| US-11771659-B2 | Treating disease and promoting weight loss by inhibiting the TMA/FMO3/TMAO pathway | THE CLEVELAND CLINIC FOUNDATION (US) | 2023-10-03 | — | — | US | disclosed |
| US-20210186991-A1 | TREATING AND PREVENTING DISEASE WITH TMA AND TMAO LOWERING AGENTS | THE CLEVELAND CLINIC FOUNDATION | 2021-06-24 | — | — | US | disclosed |
| US-10933072-B2 | Treating and preventing disease with TMA and TMAO lowering agents | THE CLEVELAND CLINIC FOUNDATION (US) | 2021-03-02 | — | — | US | disclosed |
| WO-2016049537-A1 | TREATING AND PREVENTING DISEASE WITH TMA AND TMAO LOWERING AGENTS | THE CLEVELAND CLINIC FOUNDATION (US) | 2016-03-31 | — | — | WO | disclosed |
| US-20160089387-A1 | TREATING AND PREVENTING DISEASE WITH TMA AND TMAO LOWERING AGENTS | THE CLEVELAND CLINIC FOUNDATION | 2016-03-31 | — | — | US | disclosed |
| US-8362066-B2 | Compounds and methods for treating protein folding disorders | TREVENTIS CORPORATION (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362066-B2 | Compounds and methods for treating protein folding disorders | TREVENTIS CORPORATION (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362066-B2 | Compounds and methods for treating protein folding disorders | TREVENTIS CORPORATION (US) | 2013-01-29 | — | — | US | disclosed |
| US-20100144821-A1 | COMPOUNDS AND METHODS FOR TREATING PROTEIN FOLDING DISORDERS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2010-06-10 | — | — | US | disclosed |
| US-20100144821-A1 | COMPOUNDS AND METHODS FOR TREATING PROTEIN FOLDING DISORDERS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2010-06-10 | — | — | US | disclosed |
| US-20100144821-A1 | COMPOUNDS AND METHODS FOR TREATING PROTEIN FOLDING DISORDERS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2010-06-10 | — | — | US | disclosed |
| EP-2081892-A1 | COMPOUNDS AND METHODS FOR TREATING PROTEIN FOLDING DISORDERS | Queen's University at Kingston (CA) | 2009-07-29 | — | — | EP | disclosed |
| WO-2008058402-A1 | COMPOUNDS AND METHODS FOR TREATING PROTEIN FOLDING DISORDERS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11771659-B2 | Treating disease and promoting weight loss by inhibiting the TMA/FMO3/TMAO pathway | SLC5A2, SLC5A1, MAT1A | L3MBTL1 1923/4885KDM4E 2023/4885ALDH1A1 1973/4885 |
| US-11911399-B2 | Treating and preventing disease with TMA and TMAO lowering agents | MAOB, DAO, ESD | L3MBTL1 2660/4885KDM4E 1290/4885ALDH1A1 239/4885 |
| US-20240139120-A1 | TREATING DISEASE AND PROMOTING WEIGHT LOSS BY INHIBITING THE TMA/FMO3/TMAO PATHWAY | SLC5A2, SLC5A1, MAT1A | L3MBTL1 1923/4885KDM4E 2023/4885ALDH1A1 1973/4885 |
| US-10933072-B2 | Treating and preventing disease with TMA and TMAO lowering agents | MAOB, DAO, ESD | L3MBTL1 2660/4885KDM4E 1290/4885ALDH1A1 239/4885 |
| US-20160089387-A1 | TREATING AND PREVENTING DISEASE WITH TMA AND TMAO LOWERING AGENTS | MAOB, DAO, ESD | L3MBTL1 2660/4885KDM4E 1290/4885ALDH1A1 239/4885 |
| US-12576055-B2 | Disease detection and treatment based on trimethyl-lysine levels | BHMT, BHMT2, EHMT2 | L3MBTL1 39/4885KDM4E 270/4885ALDH1A1 1296/4885 |
| US-20100144821-A1 | COMPOUNDS AND METHODS FOR TREATING PROTEIN FOLDING DISORDERS | SNCA, MAPT, APP | L3MBTL1 2503/4885KDM4E 1608/4885ALDH1A1 3687/4885 |
| US-20210186991-A1 | TREATING AND PREVENTING DISEASE WITH TMA AND TMAO LOWERING AGENTS | MAOB, DAO, ESD | L3MBTL1 2660/4885KDM4E 1290/4885ALDH1A1 239/4885 |
| US-20240165131-A1 | TREATING AND PREVENTING DISEASE WITH TMA AND TMAO LOWERING AGENTS | MAOB, DAO, ESD | L3MBTL1 2660/4885KDM4E 1290/4885ALDH1A1 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.